TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Ketorolac for Shoulder Tip Pain During Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* nulligravida healthy women who delivered single term baby, with American Society of Anesthesiologists physical status 1 or 2~Exclusion Criteria:~previous caesarean section; pre-eclampsia; gestational diabetes; trauma; fractures or chronic pain in shoulder joints, forearms, upper limbs; cardiovascular or biliary system disorders; women undergoing emergency caesarean; previous history of abdominal surgery; conditions preventing spinal block, including local infection; coagulopathies; haemodynamic instability

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketorolac (Type: EXPERIMENTAL): None
- Normal saline 0.9% (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bilateral CRSwNP.~* Prior treatment with systemic corticosteroids (SCS), and/or contraindicate to or intolerance to SCS, and/or with prior surgery to nasal polyps.~* Stable dose of intranasal corticosteroids for at least 4 weeks before screening.~* Ongoing symptoms for at least 4 weeks before screening：1)Nasal congestion/obstruction; 2)Othe symptom, e.g., loss of smell or rhinorrhea.~* Bilateral NPS of ≥5 with a minimum score of 2 in each nasal cavity at screening and at baseline.~* NCS score of 2 or 3 at screening and at baseline.~* Eosinophilic level meets the one of the following criteria: 1) serum eosinophil count ≥6.9% (without concomitant asthma) or ≥3.7% (with concomitant asthma) at screening; 2) absolute count of ≥55 per high power field or percentage of ≥27% in eosinophil level from nasal polyps biospy tissue.~* Contraception.~Exclusion Criteria:~* Not enough washingout period for previous therapy, e.g., less than 10 weeks or 5 half-lives (whichever is longer) for IL-4Rα antagonists, less than 8 weeks or 5 half-lives for biologic therapy/systemic immunosuppressant, less than 6 months for sinus surgery (including polypectomy).~* concurrent disease, e.g., ongoing rhinitis medicamentosa, acute sinusitis, nasal infection or upper respiratory infection, allergic fungal rhinosinusitis, malignancy, uncontrolled chronic disease such as cardivascular diseases, tuberculosis, diabetes etc.~* Allergic or intolerant to mometasone furoate spray or CM310/placebo.~* Significant liver or renal dysfunction.~* Other.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CM310 (Type: EXPERIMENTAL): CM310 300mg is given subcutaneously (SC) every two weeks for 16-week treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is given subcutaneously (SC) every two weeks for 16-week treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic hepatitis B aged 18 years or older~* Subjects who have evidence to demonstrate a history of chronic hepatitis B for at least six months from the time of screening visit~* Subjects who have HBsAg positive test at screening visit~* Subjects who did not receive the hepatitis B treatment, including interferon or pegylated interferon, within 24 weeks of starting the screening test~* Subjects with an ALT of 80 units or more and 10 times lower than the normal upper limit at the time of screening~Exclusion Criteria:~* Subjects infected with hepatitis C, hepatitis D or human immunodeficiency virus~* Subjects with creatinine clearance of less than 50 ml/min at the screening visit~* At the time of screening visit, alpha-fetoprotein level was higher than 50 ng/ml and related imaging test showed hepatocellular carcinoma~* Subjects with decompensated liver disease who meet the following criteria:~  1. Total bilirubin levels greater than 2.5 mg/dl~ 2. Prothrombin time is at least 3 seconds longer than normal upper limit~ 3. Serum albumin value less than 30 g/l~ 4. Subjects with a history of ascites, jaundice, bleeding from varicose veins, hepatic encephalopathy, or other signs of liver failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DA-2802 (Type: EXPERIMENTAL): DA-2802 319mg tablet qd
- Viread® (Type: ACTIVE_COMPARATOR): Viread® 300mg tablet qd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Plant Sterol Supplement on LDL-C Lowering in Low-to-Moderate Risk South Asian Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is a South Asian male or female, ≥18 years of age~2. Subject has LDL-C ≥120 and \<190 mg/dL measured in the past 3 months (or measured at the baseline visit), while not taking cholesterol-lowering medication or cholesterol-lowering supplement for at least 1 month prior, and having a ASCVD Risk score \<7.5%.~3. Subjects with LDL-C ≥120 and \<190 mg/dL with ASCVD risk scores \>7.5% who are known to be intolerant of statin therapy drugs.~4. Subjects with LDL-C \> 189 mg/dl or ASCVD \> 7.5% who have declined prescription medical therapy.~5. If current smoker, subject does not have any plans to change current smoking status or frequency.~6. Subject is willing to fast (10-14 h, target 12 h, water only) prior to each clinic visit.~7. Subject understands the study procedures and signs forms documenting informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator and is willing to complete study procedures.~8. Subject is agreeable to receiving clinical care virtually.~Exclusion Criteria:~1. Subject has taken a prescription cholesterol-lowering medication in the past 1 month.~2. Subject has a known allergy or sensitivity to soy, corn, or other ingredients in the study product.~3. Subject is taking dietary supplements for cholesterol-lowering such as red yeast rice, niacin \>100 mg/d or omega-3 fatty acid supplements providing ≥1000 mg/d eicosapentaenoic acid and/or docosahexaenoic acid. (Stable use of viscous fiber laxative ≤2 teaspoons/d is allowed.)~4. Subject is a female, who is pregnant, planning to be pregnant during the study period, or lactating. Subjects should agree to use contraception during study period to avoid pregnancy.~5. Individual has active angina, stable or unstable, requiring urgent cardiovascular functional risk stratification (stress testing or catheterization) or intervention. Or has congestive heart failure that is not compensated or in which the subject is not euvolemic, as determined by the treating MD.~6. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Plant Sterol (Type: EXPERIMENTAL): South Asian participants with moderate cardiovascular disease risk will receive standard of care in addition to the plant sterol supplement to take twice daily for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with Kawasaki disease (incipient cases only) with 5 or more of the 6 major symptoms of Kawasaki disease.~* Patients refractory to initial IVIG therapy (a single administration at 2 g per kg body weight).~* Patients with a fever of 37.5ºC or higher axillary temperature at the time of enrollment.~* Patients to whom the study drug can be administered by day 8 of disease.~Exclusion Criteria:~* Patients who have received vaccination with Bacille Calmette-Guérin (BCG) vaccine within 6 months before the enrollment.~* Patients with a complication, or a history within 6 months before the enrollment of, serious infections requiring hospitalization.~* Patients with a complication, or a history within 6 months before the enrollment of, opportunistic infections.~* Patients complicated with active tuberculosis, active hepatitis B or C, or patients confirmed to be hepatitis B virus carriers or a history of hepatitis B.~* Patients confirmed to have HIV infection, or patients with a family history of HIV infection.~* Patients who have a history of receiving treatment with infliximab or other biological products.~* Patients who had participated in another clinical study and had received a study drug within 12 weeks before giving consent.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- TA-650 (Type: EXPERIMENTAL): None
- VGIH (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals of 18-70 years of age,~* with Type 2 Diabetes,~* with an HbA1c (6.5%-9%),~* and with a systolic blood pressure (120-160 mmHg).~Exclusion Criteria:~* Individuals with:~  1. Type 1 Diabetes,~ 2. eGFR \<50mL/min/1.73m,~ 3. pregnancy or breast feeding,~ 4. significant cardiac, pulmonary or liver disease,~ 5. prior history of pancreatitis, medullary thyroid cancer, multiple endocrine neoplasia syndromes,~ 6. SBP \>161 mmHg, 7) DBP \>100 mmHg,~ 7. alcohol or substance abuse,~ 8. states of secondary hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
- Placebo arm (Type: PLACEBO_COMPARATOR): placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PET Imaging of Endotoxin-induced iNOS Activation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy man or woman, any race or ethnicity, age 19 - 44 years old~* Screening Pulmonary Function Test~* Screening oxygen saturation by pulse oximetry \>97% on room air~* Capable of lying still and supine within the PET/CT scanner for 1.5 hours~* Capable of following instructions for breathing protocol during CT portion of PET/CT~* Able and willing to give informed consent~* BMI \< 35~Exclusion Criteria:~* Pregnancy (confirmed by qualitative serum hCG pregnancy test)~* Lactation~* Active menstruation~* History of cardiopulmonary disease~* Currently taking any prescription medications~* History of tobacco use or illicit drug use within the past year~* Presence of implanted electronic medical device~* Enrollment in another research study of an investigational drug~* Known allergy to both trimethoprim/sulfamethoxazole and amoxicillin~* Known allergy to drugs routinely used during bronchoscopy~* Inability lie flat for 1.5 hours for PET/CT scans or follow breathing protocol instructions for the CT portion of the PET/CT

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- Endotoxin and [18F](+/-)NOS (Type: EXPERIMENTAL): All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer F-18 (+/-) NOS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sound Check-Correlation Between Transperineal and Digital Cervical Exam in 3rd Trimester Pregnancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women in the third trimester presenting for assessment of labor or admitted for labor and delivery.~Exclusion Criteria:~* Second trimester (less than 28 weeks)~* BMI\>50~* Does not wish to participate

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Transperineal ultrasound cervical exam followed by Digital (manual) cervical exam (Type: EXPERIMENTAL): Patients will undergo transperineal cervical exam via Butterfly iQ ultrasound. Patients will then undergo traditional digital cervical exam via examiner's fingers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Triple Combinations Against Hookworm Infections in Lao

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed by parents and/or legal representative; and a verbal assent (children \<12 years) or signed assent (children ≥12 years), according to Lao regulations.~* Able and willing to be examined by a study physician at the beginning of the study.~* Able and willing to provide two stool samples at the beginning (baseline) and two to three weeks after treatment (follow-up).~* Positive for hookworm eggs in the stool.~* Absence of major systemic illnesses, e.g. diabetes, severe anemia as assessed by a medical doctor, upon initial clinical assessment.~* No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease.~* No recent anthelminthic treatment (within past 4 weeks).~* No known allergy to study medications (e.g. albendazole, mebendazole, pyrantel pamoate, oxantel pamoate).~* Negative pregnancy test (girls ≥12 years)~Exclusion Criteria:~* No written informed consent by parents and/or legal representative and no verbal assent (children \<12 years) or signed assent (children ≥12 years).~* Presence of major systemic illnesses, e.g. diabetes, severe anemia as assessed by a medical doctor, upon initial clinical assessment.~* History of acute or severe chronic disease.~* Recent use of anthelminthic drug (within past 4 weeks).~* Attending other clinical trials during the study.~* Negative diagnostic result for hookworm eggs in the stool.~* Positive pregnancy test (girls ≥12 years)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Albendazole triple combi (Type: ACTIVE_COMPARATOR): Albendazole (400 mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
- Pyrantel pamoate double combi (Type: EXPERIMENTAL): Pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
- Albendazole double combi (Type: EXPERIMENTAL): Albendazole (400 mg) + oxantel pamoate (20 mg/kg)
- Mebendazole triple combi (Type: EXPERIMENTAL): Mebendazole (500mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin & Inflammation in Pre-diabetic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pediatric patients with glucose intolerance per ADA criteria,~* free of acute or chronic inflammatory processes 3 months prior to recruitment,~* 4-17 years of age~Exclusion Criteria:~* previous personal history of diabetes or demonstrating diabetes in OGTT curve,~* chronic renal disease or serum creatinine over 1.4 mg/dl (females) or 1.5 (males),~* active hepatic disease,~* smoking,~* primary dislipidemia,~* heart problems,~* steroids,~* chronic metabolic acidosis,~* receiving anti-hypertensive or hypolipemia or hypoglucemia medications

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- metformin group (Type: ACTIVE_COMPARATOR): this group received 850 mg metformin twice daily, along with recommended diet and exercise
- placebo group (Type: PLACEBO_COMPARATOR): This group received 850 mg of placebo twice daily, along with a recommended regimen of diet and exercise

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Coronary MDCTA With Iopamidol Injection 370

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent~* At least 30 years of age~* Weight less than 250 lbs~* Known or suspected coronary artery disease and suspected to have significant coronary artery stenosis~* Undergo MDCTA scan~* Undergo coronary angiography within 2 weeks of MDCTA scan~Exclusion Criteria:~* Hx of hypersensitivity to iodinated contrast agents~* Known or suspected hyperthyroidism or pheochromocytoma~* Renal impairment~* History of coronary artery stent placement or bypass grafts~* Unstable~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isovue 370, 70 mL (Type: EXPERIMENTAL): iopamidol injection 370, 70 mL
- Isovue 370, 80 mL (Type: EXPERIMENTAL): iopamidol injection 370, 80 mL
- Isovue 370, 90 mL (Type: EXPERIMENTAL): iopamidol injection 370, 90 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Palonosetron in Cancer Treated With Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cancer patients receiving platinum-based chemotherapy adequate bone marrow, hepatic and renal function~Exclusion Criteria:~* Pregnancy~* Serious concomitant diseases, in the invesgator´s criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravenous palonosetron (Type: ACTIVE_COMPARATOR): Intravenous palonosetron: control arm (standard treatment)
- subcutaneous palonosetron (Type: EXPERIMENTAL): subcutaneous palonosetron

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete